Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade

BACKGROUND: Toll-like receptors (TLRs) are critical innate immune sensors that elicit antitumor immune responses in cancer immunotherapy. Although a few TLR agonists have been approved for the treatment of patients with early-stage superficial cancers, their therapeutic efficacy is limited in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Won Suk, Kim, Dong Sung, Kim, Jeong Hun, Heo, Yoonki, Yang, Hannah, Go, Eun-Jin, Kim, Jin Hyoung, Lee, Seung Joon, Ahn, Byung Cheol, Yum, Jung Sun, Chon, Hong Jae, Kim, Chan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240943/
https://www.ncbi.nlm.nih.gov/pubmed/35764365
http://dx.doi.org/10.1136/jitc-2022-004799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240943/
https://www.ncbi.nlm.nih.gov/pubmed/35764365
http://dx.doi.org/10.1136/jitc-2022-004799

Ejemplares similares